Raymond James Has Lowered Expectations for Avantor (NYSE:AVTR) Stock Price

by · The Markets Daily

Avantor (NYSE:AVTR – Get Free Report) had its price objective decreased by Raymond James from $29.00 to $26.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Raymond James’ price objective points to a potential upside of 17.20% from the stock’s previous close.

Several other equities analysts have also recently weighed in on AVTR. UBS Group reaffirmed a “neutral” rating and set a $25.00 target price (down previously from $29.00) on shares of Avantor in a research note on Friday. Robert W. Baird cut their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Royal Bank of Canada restated an “outperform” rating and set a $34.00 price target on shares of Avantor in a research note on Thursday, September 26th. Barclays lowered their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Finally, Wells Fargo & Company decreased their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, October 28th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $27.38.

View Our Latest Stock Report on Avantor

Avantor Trading Up 0.3 %

AVTR stock traded up $0.08 during mid-day trading on Tuesday, reaching $22.19. 2,467,992 shares of the stock traded hands, compared to its average volume of 4,294,136. The stock’s fifty day moving average is $21.45 and its 200-day moving average is $23.40. Avantor has a 52-week low of $19.59 and a 52-week high of $28.00. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. The company has a market cap of $15.10 billion, a P/E ratio of 48.23, a P/E/G ratio of 3.51 and a beta of 1.28.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp grew its position in Avantor by 58.0% during the 3rd quarter. State Street Corp now owns 22,368,244 shares of the company’s stock worth $578,666,000 after acquiring an additional 8,206,695 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Avantor by 653.0% during the third quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock worth $159,740,000 after purchasing an additional 5,354,678 shares during the last quarter. FMR LLC increased its stake in shares of Avantor by 557.2% in the third quarter. FMR LLC now owns 4,675,283 shares of the company’s stock valued at $120,950,000 after buying an additional 3,963,912 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Avantor by 18.2% in the third quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock valued at $457,710,000 after buying an additional 2,719,615 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its position in Avantor by 146.5% during the 3rd quarter. Principal Financial Group Inc. now owns 2,628,372 shares of the company’s stock worth $67,996,000 after buying an additional 1,562,018 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

About Avantor

(Get Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Featured Stories